By using this La Jolla Pharmaceutical Company (“La Jolla”, “we”, or “our”) website, you agree to be bound by the terms of use (“Terms of Use” or “Terms”) contained in this agreement and any subsequent modifications La Jolla may make from time to time. You may not use this website ("Site") unless you agree to these Terms of Use.

Thank you for visiting the GIAPREZA (angiotensin II)  website. The GIAPREZA website is designed to provide a general overview of GIAPREZA. The content and the website in general is not intended to be used for medical and/or clinical advice. Doctors or other health care providers that visit this site should not rely on any medical information contained within this website, and need to exercise their independent and professional judgment in treating patients. Also, the information contained in this website is not intended to be used in making any decision relating to an investment in securities of La Jolla. La Jolla makes no representations as to the accuracy or completeness of any information on this website or accessed through this website, and may alter or delete materials or links at any time.


While La Jolla takes precautions to make sure the information it provides on this website is accurate and complete, it expressly disclaims any warranty or representation regarding the information. THE INFORMATION ON THIS WEBSITE IS PROVIDED "AS IS," WITHOUT A WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. You agree that your use of this website is done at your own risk, and that La Jolla will not be liable for any damages of any kind resulting from your use of this website or reliance on information contained on this website.


The GIAPREZA website, and any content, trademarks and logos are either licensed from third parties or are the possession of La Jolla. Any content on the GIAPREZA website is protected by intellectual property rights, including trademark, copyright and patent, and may not be used without La Jolla’s express permission.

The GIAPREZA website may contain links or produce search results that reference links to third-party websites. La Jolla makes no representations or warranties about the privacy, data security or accuracy of those other websites. La Jolla does not endorse or recommend any of the websites linked to this website. La Jolla encourages you to check the privacy policies and terms of use of any other website you use, even if you access them through links on this website.

This website contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this website and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) sales; regulatory actions relating to La Jolla’s products by the U.S. Food and Drug Administration (FDA), European Commission and/or other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this website apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

Your privacy and the privacy of all our users is important. Please review our Privacy Notice.

You represent, warrant and covenant that: (i) you have the power and authority to enter into this Agreement; (ii) you are at least 18 years of age; and (iii) you will only use the GIAPREZA website in accordance with these Terms of Use.

If any provision of these Terms of Use are held to be illegal, then that provision may be severed from the rest of the Terms of Use without affecting the enforceability of other provisions.

Any communication or material you transmit to La Jolla via the Site, other than personally identifiable information, will be treated by La Jolla as non-confidential and non-proprietary. Thus, in the absence of a written agreement with La Jolla to the contrary, you agree that you will not submit to La Jolla any information or ideas that you consider to be confidential or proprietary.

La Jolla may terminate your access to and use of the Site, at La Jolla’s sole discretion, at any time and without notice to you. Upon any termination, discontinuation or cancellation of the Site, all provisions of these Terms which by their nature should survive will survive, including, without limitation, ownership provisions, warranty disclaimers, limitations of liability, and dispute resolution provisions.

These Terms of Use and any action related thereto will be governed by the laws of the State of California without regard to its conflict of laws provisions. The parties expressly consent to personal and exclusive jurisdiction in the federal and state courts located in the San Diego County, California.

If you have any questions about La Jolla or these Terms of Use, please contact La Jolla at:


La Jolla Pharmaceutical Company

4550 Towne Centre Court

San Diego, CA 92121




GIAPREZA (angiotensin II) increases blood pressure in adults with septic or other distributive shock.



Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.

Adverse Reactions

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions​

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:


La Jolla Pharmaceutical Company




U.S. Food and Drug Administration



For additional information, please see GIAPREZA FDA prescribing information.

 Privacy Notice                    Terms of Use

LJPC logo (1).png

This site is intended for healthcare professionals in the United States




There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.